Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04150822Active Not Recruiting

CHORUS - Comprehensive HHT Outcomes Registry of the United States (Formerly OUR HHT Registry)

Role: collaborator

NCT03850964Phase 2Active Not Recruiting

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

Role: lead

NCT06259292Recruiting

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

Role: lead

NCT03850730Phase 1Unknown

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

Role: lead

All 4 trials loaded